



CASE 4-32702A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 704618549 US
Express Mail Label Number

October 5, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
KUDARAVALLI ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/10798

FILED: 29 SEPTEMBER 2003

U.S. APPLICATION NO: 10/529,613

35 USC §371 DATE: Not Yet Known

FOR: METHODS TO TREAT CHOLESTEROL ELEVATIONS DURING
IMMUNOSUPPRESSANT THERAPY

Mail Stop: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits. Under 37 C.F.R. §1.97(b)(3), no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/10798, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



John T. Prince
Attorney for Applicants
Reg. No. 43,019

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346

Date: October 5, 2005

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
4-32702A
APPLICATION NO.
10/529,613
APPLICANT
KUDARAVALLI ET AL.
FILING DATE
MARCH 30, 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,268,142	7/01	Duff, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	El-Omar, et al., "Interleukin-1 polymorphisms associated with increased risk of gastric cancer", Nature, Vol. 404 (2000)		
AS	Mattila, et al., "Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients", J. of Med. Genetics (2002)		
AT	Kerschdorfer, et al., "Lipoprotein(a) plasma concentration after renal transplantation: a prospective evaluation after 4 years of follow-up", Atherosclerosis, Vol. 144 (1999)		

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
4-32702A
APPLICATION NO.
10/529,613
APPLICANT
KUDARAVALLI ET AL.
FILING DATE
MARCH 30, 2005

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Database EMBL Online: Clark, et al., "Human gene for prointerleukin 1 beta", Accession No. X04500-XP002276413 (1997)
	DB	Radeau, et al., "HDL cholesterol and TaqlB cholestryl ester transfer protein gene polymorphism in renal transplant recipients", Nephron, Vol. 84 (2000)
	DC	
	DD	
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.